X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The partnership aims to explore the use of NexImmune’s AIM nanoparticles in combination with an anti-CD3 mAb,a murine surrogate of teplizumab, to tolerize, deplete or modulate diabetes antigen-specific T cells.
Lead Product(s): Undisclosed
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: JDRF
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership October 24, 2023
Details:
NEXI-004 is a patient derived stem cell developed using adoptive cell therapy modality technology which is being developed for EBV associated diseases. It is currently in preclinical stage of development.
Lead Product(s): NEXI-004
Therapeutic Area: Infections and Infectious Diseases Product Name: NEXI-004
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 18, 2023
Details:
The goal of this collaboration is to develop adoptive cell therapies that may benefit patients afflicted with immunological disorders related to Epstein-Barr virus (EBV) and Human T-cell Leukemia Virus, type 1 (HTLV-1).
Lead Product(s): T-Cell Therapy
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: National Institute of Neurological Disorders and Stroke
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 06, 2022
Details:
The agreement supports the development of molecules targeting acute myeloid leukemia, multiple myeloma, human papilloma virus (HPV) associated tumors, and additional human leukocyte antigens (HLAs) that have the potential to increase immunotherapy options for patients.
Lead Product(s): HLA IgG4 Fusion Proteins,T-cell Co-stimulatory Monoclonal Antibodies
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: KBI Biopharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 08, 2022
Details:
IND clearance enables commencement of a clinical trial to evaluate NEXI-003, an autologous antigen-specific T cell product (CD3+/CD4-), in patients with relapsed or refractory human papillomavirus (HPV)-related cancers.
Lead Product(s): NEXI-003
Therapeutic Area: Oncology Product Name: NEXI-003
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 14, 2022
Details:
The JDRF award will fund efforts to investigate the use of NexImmune’s AIM nanoparticles in combination with a murine surrogate of teplizumab. The investigation will test this hypothesis in a preclinical model by combining anti-CD3 mAb treatment.
Lead Product(s): T1D Antigen-specific Nanoparticle,Teplizumab
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: JDRF
Deal Size: $0.6 million Upfront Cash: Undisclosed
Deal Type: Partnership May 10, 2022
Details:
The research will focus on the use of NexImmune’s adoptive cell therapy, AIM ACT, in Columbia’s patient-derived organoid (PDO) models of HPV-associated cancers, including head and neck squamous cell carcinoma.
Lead Product(s): Adoptive Cell Therapy
Therapeutic Area: Oncology Product Name: AIM ACT
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Columbia University Irving Medical Center
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 26, 2022
Details:
The collaboration is centered around NexImmune’s artificial antigen presenting cells' (aAPCs) ability to expand neoantigen-specific CD8+ T cells in apheresis material provided by melanoma patients.
Lead Product(s): Neoantigen-specific CD8+ T Cells
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: The Laura and Isaac Perlmutter Cancer Center
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 14, 2022
Details:
Preliminary data from its first-in-human study of NEXI-001, a multi-antigen specific CD8+ T cell product, in acute myeloid leukemia (AML) patients with relapsed disease has been selected for an oral presentation at the 62nd ASH Annual Meeting.
Lead Product(s): NEXI-001
Therapeutic Area: Oncology Product Name: NEXI-001
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 04, 2020
Details:
NEXI-002 is a patient-derived cellular product that contains populations of naturally-occurring CD8+ T cells directed against several multiple myeloma (MM)-specific antigen targets. It is the second clinical product NexImmune has generated with its AIM nanoparticle technology.
Lead Product(s): NEXI-002
Therapeutic Area: Oncology Product Name: NEXI-002
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
